Cara Therapeutics | CARA - Selling And Administration Expenses


Cara Therapeutics reported $2.19M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Cassava Sciences USD 6.66M 1.24M Dec/2025
Chugai Pharma JPY 28.9B 8.02B Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
J&J USD 6.03B 719M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
RedHill Biopharma USD 4.48M 1.52M Mar/2024
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024